Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and accelerates to improve health and improve lives through its unparalleled diagnostics and drug development capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļLH
āļāļ·āđāļāļāļĢāļīāļĐāļąāļLabcorp Holdings Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļApr 24, 1991
āļāļĩāļāļĩāđāļMr. Adam H. Schechter
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ70000
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļApr 24
āļāļĩāđāļāļĒāļđāđ358 S Main St
āđāļĄāļ·āļāļBURLINGTON
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNYSE Consolidated
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ27215
āđāļāļĢāļĻāļąāļāļāđ13362291127
āđāļ§āđāļāđāļāļāđhttps://www.labcorp.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļLH
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļApr 24, 1991
āļāļĩāļāļĩāđāļMr. Adam H. Schechter
Mr. Adam H. Schechter
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
Dr. Brian J. Caveney, M.D., J.D.
Dr. Brian J. Caveney, M.D., J.D.
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Mr. Lance V. Berberian
Executive Vice President - Special Advisor, Strategy
Executive Vice President - Special Advisor, Strategy
Mr. Peter M. Neupert
Independent Director
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Lead Independent Director
Lead Independent Director
Ms. Kerrii B. Anderson, CPA
Ms. Kerrii B. Anderson, CPA
Independent Director
Ms. Amy B. Summy
Executive Vice President, Chief Marketing Officer
Executive Vice President, Chief Marketing Officer
Mr. Mark S. Schroeder
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
Mr. Akinbolade Oyegunwa
Executive Vice President and Chief Information and Technology Officer
Executive Vice President and Chief Information and Technology Officer
Ms. Megan D. Bailey
Executive Vice President and President - Central Laboratories and International
Executive Vice President and President - Central Laboratories and International
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Adam H. Schechter
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
Dr. Brian J. Caveney, M.D., J.D.
Dr. Brian J. Caveney, M.D., J.D.
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Mr. Lance V. Berberian
Executive Vice President - Special Advisor, Strategy
Executive Vice President - Special Advisor, Strategy
Mr. Peter M. Neupert
Independent Director
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Lead Independent Director
Lead Independent Director
Ms. Kerrii B. Anderson, CPA
Ms. Kerrii B. Anderson, CPA
Independent Director
iShares U.S. Healthcare Providers ETF
Knowledge Leaders Developed World ETF
Thrivent Small-Mid Cap ESG ETF
SPDR S&P Health Care Services ETF
Invesco S&P 500 Equal Weight Health Care ETF
Nuveen ESG Mid-Cap Value ETF
Schwab Ariel Opportunities ETF
iShares ESG Aware MSCI USA Value ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
iShares U.S. Healthcare Providers ETF
āļŠāļąāļāļŠāđāļ§āļ3.89%
Knowledge Leaders Developed World ETF
āļŠāļąāļāļŠāđāļ§āļ3.18%
Thrivent Small-Mid Cap ESG ETF
āļŠāļąāļāļŠāđāļ§āļ2.26%
SPDR S&P Health Care Services ETF
Brandes US Value ETF
āļŠāļąāļāļŠāđāļ§āļ1.75%
Invesco S&P 500 Equal Weight Health Care ETF
āļŠāļąāļāļŠāđāļ§āļ1.73%
Madison Covered Call ETF
āļŠāļąāļāļŠāđāļ§āļ1.69%
Nuveen ESG Mid-Cap Value ETF
āļŠāļąāļāļŠāđāļ§āļ1.57%
Schwab Ariel Opportunities ETF
āļŠāļąāļāļŠāđāļ§āļ1.49%
iShares ESG Aware MSCI USA Value ETF
āļŠāļąāļāļŠāđāļ§āļ1.43%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
692.30M
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Mar 12, 2025 going ex on Feb 27, 2025
LH.NB Final Cash Dividend of gross USD 0.72 paid on Dec 13, 2024 going ex on Nov 26, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 13, 2024 going ex on Aug 29, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 12, 2024 going ex on May 24, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Mar 13, 2024 going ex on Feb 26, 2024
LH.NB Final Cash Dividend of gross USD 0.72 paid on Dec 12, 2023 going ex on Nov 07, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 08, 2023 going ex on Aug 07, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 08, 2023 going ex on May 17, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Mar 13, 2023 going ex on Feb 22, 2023
LH.NB Final Cash Dividend of gross USD 0.72 paid on Dec 09, 2022 going ex on Nov 16, 2022
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ